Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Frontline Ltd., a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2021, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Hamilton, Bermuda.

Frontline Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REMISSION RESULTS NEARLY DOUBLE PUBLISHED VEN/AZA OUTCOMES IN PATIENTS WITH HISTORICALLY LIMITED TREATMENT SUCCESS SEATTLE, WA / ACCESS NEWSWIRE / SEPTEMBER 3, 2026 / APTEVO THERAPEUTICS INC. (NASDAQ:APVO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MULTISPECIFIC IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED A 93% CLINICAL BENEFIT RATE WITH ITS MIPLETAMIG TRIPLET IN EVALUABLE FRONTLINE ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH TP53 MUTATIONS, ONE OF THE MOST DIFFICULT-TO-TREAT FORMS OF THE DISEASE AND A PATIENT POPULATION THAT HAS HISTORICALLY RESPONDED POORLY TO TREATMENT. "TP53-MUTATED AML REMAINS ONE OF THE MOST CHALLENGING AML SUBPOPULATIONS TO TREAT," SAID DIRK HUEBNER, M.D.

APTEVO REPORTS 93% CLINICAL BENEFIT RATE WITH MIPLETAMIG TRIPLET IN DIFFICULT-TO-TREAT TP53-MUTATED FRONTLINE AML

FRONTLINE PLC (THE COMPANY OR FRONTLINE) (NYSE: FRO  OSE: FRO) TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WHEREBY THE COMPANY WILL SELL TWO VLCCS BUILT IN 2017 FOR AN AGGREGATE SALE PRICE OF $270 MILLION. THE VESSELS ARE EXPECTED TO BE DELIVERED TO THE NEW OWNER DURING THE THIRD QUARTER OF 2026.

FRO  SALE OF TWO VLCCS

SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3 MANGROVE STUDY (BGB-3111-306; NCT04002297) EVALUATING FOUNDATIONAL BTK INHIBITOR BRUKINSA (ZANUBRUTINIB) PLUS RITUXIMAB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA (MCL). MANGROVE IS THE FIRST PHASE 3, GLOBAL, RANDOMIZED TRIAL TO EVALUATE A BTK INHIBITO.

BEONE MEDICINES ANNOUNCES POSITIVE PHASE 3 RESULTS FOR BRUKINSA IN FRONTLINE MANTLE CELL LYMPHOMA

NEW YORK, JUNE 25, 2026 (GLOBE NEWSWIRE) -- MISTER CAR WASH , ONE OF THE LARGEST CAR WASH COMPANIES IN THE UNITED STATES, HAS SUCCESSFULLY TRANSFORMED ITS FRONTLINE EMPLOYEE EXPERIENCE BY PARTNERING WITH STAFFBASE , A LEADING PROVIDER OF EMPLOYEE COMMUNICATION PLATFORMS. THROUGH THE LAUNCH OF ITS BRANDED APP, MISTER CONNECT, THE COMPANY HAS ESTABLISHED A SINGLE SOURCE OF TRUTH FOR ITS 7,000+ EMPLOYEES ACROSS MORE THAN 550 LOCATIONS IN 23 STATES.

MISTER CAR WASH DIRECTS FRONTLINE ENGAGEMENT TO NEW HEIGHTS WITH STAFFBASE, ACHIEVING 93% ACTIVE USER ADOPTION ACROSS 550+ LOCATIONS

SPARC AI ENGAGES UKRAINE-BASED CFC DEFENCE TO LEAD ITS MARKET-ENTRY PROGRAMME FOR OVERWATCH, ACCELERATING DRONE OEM PARTNERSHIPS AND FRONTLINE ADOPTION.

SPARC AI STRENGTHENS UKRAINE MARKET ENTRY, ENGAGES CFC DEFENCE TO DRIVE FRONTLINE ADOPTION OF OVERWATCH AND EXPAND ITS ROSTER OF PARTNERED DRONE MANUFACTURERS

CHICAGO, JUNE 11, 2026 (GLOBE NEWSWIRE) -- QUETZAL THERAPEUTICS, A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR RARE HEMATOLOGIC MALIGNANCIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN QUATRO-APL, THE COMPANY'S GLOBAL PHASE 3 CLINICAL TRIAL EVALUATING QTX-2101, AN INVESTIGATIONAL ORAL CAPSULE FORMULATION OF ARSENIC TRIOXIDE, IN COMBINATION WITH ALL-TRANS RETINOIC ACID (ATRA), FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED, LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA, OR APL.

QUETZAL THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 QUATRO-APL TRIAL OF QTX-2101 FOR FRONTLINE ACUTE PROMYELOCYTIC LEUKEMIA

CAMBRIDGE, MASS., MAY 21, 2026 (GLOBE NEWSWIRE) -- BLACK DIAMOND THERAPEUTICS, INC. (NASDAQ: BDTX), A CLINICAL-STAGE ONCOLOGY COMPANY DEVELOPING MASTERKEY THERAPIES THAT TARGET FAMILIES OF ONCOGENIC MUTATIONS IN PATIENTS WITH CANCER, TODAY ANNOUNCED POSITIVE RESULTS FROM ITS PHASE 2 TRIAL OF SILEVERTINIB IN FRONTLINE (1L) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) NON-CLASSICAL MUTATIONS (NCMS). THESE DATA WILL BE PRESENTED BY JULIA ROTOW, M.D., CLINICAL DIRECTOR, LOWE CENTER FOR THORACIC ONCOLOGY AT THE DANA-FARBER CANCER INSTITUTE, AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING ON SATURDAY, MAY 30, 2026, 1:15 PM-2:45 PM CDT.

BLACK DIAMOND THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 RESULTS FOR SILEVERTINIB IN FRONTLINE NSCLC PATIENTS WITH EGFR NON-CLASSICAL MUTATIONS

NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- CONTINUING A DECADES-LONG COMMITMENT TO DRIVING INNOVATION IN PUBLIC SAFETY, EMERGENCY RESPONSE AND COMMUNITY RESILIENCE, VERIZON TODAY ANNOUNCED THE WINNER OF ITS FIRST-EVER VERIZON FRONTLINE APP DEVELOPER CHALLENGE.

VERIZON CHAMPIONS THE INNOVATORS OF TOMORROW, NAMES WINNER OF VERIZON FRONTLINE APP DEVELOPER CHALLENGE

PROGRAM ENTERS FINAL STAGE OF DOSE OPTIMIZATION DATA CONTINUE TO DEMONSTRATE STRONG CLINICAL ACTIVITY AND FAVORABLE SAFETY ACROSS AN EXPANDING FRONTLINE DATASET SEATTLE, WA / ACCESS NEWSWIRE / MAY 6, 2026 / APTEVO THERAPEUTICS INC. (NASDAQ:APVO) TODAY REPORTED NEW CLINICAL RESULTS FROM ITS RAINIER FRONTLINE ACUTE MYELOID LEUKEMIA (AML) TRIAL. THE COMPANY IS ON TRACK TO COMPLETE THE PHASE 1B DOSE-OPTIMIZATION TRIAL AND SELECT THE RECOMMENDED PHASE 2 DOSE (RP2D) THIS YEAR.

APTEVO REPORTS 87% CLINICAL BENEFIT AND 81% REMISSION IN 31 EVALUABLE FRONTLINE AML PATIENTS THROUGH COHORT 5, SUBSTANTIALLY OUTPERFORMING BENCHMARK; RAINIER ON TRACK FOR 2026 COMPLETION AND PHASE 2 DOSE SELECTION

ZOVEGALISIB + ATIRMOCICLIB + AI SELECTED AS TRIPLET REGIMEN FOR FRONTLINE DEVELOPMENT COMPELLING EFFICACY AND TOLERABILITY DATA FOR ZOVEGALISIB TRIPLET IN MEDIAN 3L PATIENTS 44% ORR IN HEAVILY PRE-TREATED, CDK4/6-EXPERIENCED PATIENTS (MEDIAN THIRD-LINE); ORR IS SIMILAR ACROSS KINASE AND NON-KINASE PIK3CA MUTATIONS PHASE 3 FRONTLINE TRIAL IN ENDOCRINE SENSITIVE PATIENTS EXPECTED TO INITIATE IN EARLY 2027, SUBJECT TO REGULATORY FEEDBACK SUPPLY AGREEMENT IN PLACE WITH PFIZER TO SUPPLY ATIRMOCICLIB FOR THE PHASE 3 FRONTLINE TRIAL RELAY THERAPEUTICS TO HOST A CONFERENCE CALL TODAY, APRIL 27, AT 8:30AM ET CAMBRIDGE, MASS., APRIL 27, 2026 (GLOBE NEWSWIRE) -- RELAY THERAPEUTICS, INC. (NASDAQ: RLAY), A CLINICAL-STAGE, SMALL MOLECULE PRECISION MEDICINE COMPANY DEVELOPING POTENTIALLY LIFE-CHANGING THERAPIES FOR PATIENTS LIVING WITH CANCER AND GENETIC DISEASE, TODAY ANNOUNCED PLANS TO MOVE ZOVEGALISIB + ATIRMOCICLIB, PFIZER'S INVESTIGATIONAL, POTENTIAL FIRST-IN-CLASS CDK4 INHIBITOR, INTO PHASE 3 DEVELOPMENT FOR FRONTLINE PATIENTS WITH PI3K-MUTATED, HR+/HER2- METASTATIC BREAST CANCER.

RELAY THERAPEUTICS ANNOUNCES CLINICAL DATA FOR ZOVEGALISIB PLUS ATIRMOCICLIB TRIPLET COMBINATION SUPPORTIVE OF FURTHER DEVELOPMENT IN FRONTLINE METASTATIC BREAST CANCER

Frontline Ltd.

FRO

Price

Financial Reports

No items found.

Press Releases

Frontline Ltd.

FRO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

FRO